Outcomes

"Don't You Know Who I am?" (5.17.2024)

Save

Dr. Jack Cush reviews the news and journal reports from the past 2 weeks. This week's question: can we prevent gout, ILD or psoriasis?

Infectious Mortality in Autoimmune Rheumatic Disorders

Save

Interferons and Lupus Subsets

Save

In a new study, researchers from Johns Hopkins Medicine say they have uncovered insights as to the relationship between interferons and lupus, which affects up to 1.5 million Americans. 

RECIPE Study: Non-opioid Analgesics following Total Hip Arthroplasty

Save

Patients undergoing total hip arthroplasty using a combination of paracetamol, ibuprofen, and dexamethasone, had optimal responses with the lowest morphine consumption, and fewer adverse events.

Does Good Sleep Prevent Osteoporosis

Save

As part of the University of Colorado Department of Medicine’s annual Research Day, held on April 23, faculty member Christine Swanson, MD, MCR, described her National Institutes of Health-funded clinical research on whether adequate sleep can help prevent osteoporosis.

“Osteoporosis

Multiplicative Adverse Effects of Social Determinants of Health in Lupus Nephritis: A Meta-analysis and Systematic Review

Save

A metanalysis shows that social determinants of health adversely impacts patients with lupus nephritis. Lupus nephritis is a significant complication of SLE, often with dramatic increases in morbid and mortal risks. Outcomes are likely to be augmented by social determinants of health, including

Methotrexate Does Not Increase ILD Risk in Dermatomyositis

Save

A cohort analysis of dermatomyositis (DM) patients starting immunomodulators finds that methotrexate use was not associated with an increased risk of interstitial lung disease (ILD).

ILD affects ~23% of DM patients and the oft used MTX is has a low risk of pneumonitis and pulmonary

Complex Autoantibody Patterns in RA

Save

Patients with rheumatoid arthritis (RA) all have a unique and diverse set of antibodies that are involved in the development of the disease. Researchers at Utrecht University unveiled the complexity of these antibodies using powerful lab tools capable of analysing our immune system at

Systemic Inflammation and Mortality in RA-ILD

Save

Analysis of the German RABBIT registry shows that systemic inflammation, more so than disease activity, strongly influences all-cause mortality in patients with rheumatoid arthritis and prevalent interstitial lung disease (RA-ILD).

RA-ILD patients from the biologics register Rheumatoid

Biomarker Predictors of Osteoarthritis

Save

Science Advances has reported that Duke University researchers have validated a biomarkers of osteoarthritis that may be identified 2 years before the appearance of radiographic OA.  Six peptides (biomarker) demonstrated an AUC 77% probability of successfully predicting knee

ARCTIC Rewind: Can You Taper DMARDs with Remission?

Save

In an open-label, randomized, non-inferiority trial, rheumatoid arthritis patients in remission were subject to tapering of disease-modifying antirheumatic drugs (DMARDs), and while maintenance of remission was seen in some, many DMARD tapering patients did flare and were unable to maintain

TLR Antagonist in Lupus

Save

An investigational Toll-like receptor (TLR) antagonist was effective in reducing biomarkers and clinical symptoms of systemic lupus erythematosus (SLE) in a pilot trial, evidence that the innate immune system may hold the key to lupus pathophysiology.

Rheum Chapter Notes (4.26.2024)

Save

Dr. Jack Cush reviews this past week’s news and journal articles from RheumNow.com.

Predicting Infection in Lupus Nephritis

Save

Machine learning (ML) models were applied to 3 cohorts of lupus nephritis (LN) patients and established algorithms to predict co-infection in LN. 

This study analyzed 111 non-infected LN patients, 72 infected LN patients, and 206 healthy controls (HCs), looking at patient

Predicting CKD Outcomes in Lupus Nephritis

Save

An observational cohort study suggests that proteinuria levels in lupus nephritis (LN) patients did not predict their histologic class.

A multicentre observational study of patients with biopsy-proven LN; either proliferative (PLN) or membranous (MLN) lupus nephritis were compared regarding

Canary in a Coal Mine (4.19.2024)

Save

Dr. Jack Cush reviews regulatory reports, news and novel journal articles - this week focusing on Sjogren's, ILD, Gout and Uveitis.

SGLT2 Inhibitors Lowers Gout Risks in Type 2 Diabetes

Save

A population-based cohort has demonstrated that sodium-glucose cotransporter-2 inhibitors (SGLT2i) use in gout patients is superior to sulfonylurea therapy in lowering the risk of incident gout and recurrent flares among patients with type 2 diabetes (T2D). 

RA-ILD at Higher Risk for Serious Infection and Death

Save

A prospective, multicenter study from Spain has demonstrated higher rates of mortality and serious infection in rheumatoid arthritis–associated interstitial lung disease (RA-ILD) patients.

Biopsy Results in Sjogren's Syndrome

Save

Burnout or Retire (4.12.2024)

Save

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com. Is it time to worry about burnout and those who are leaving healthcare?

ILD Onset in MDA-5 Dermatomyositis

Save

Anti–melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis (DM) is a rare, aggressive and progressive subtype of DM. Its' severity is dependent on the development of progressive interstitial lung disease (ILD), manifesting as either rapidly progressive ILD (RPILD

World Congress on OP, OA & MSK Disorders

Save

Bone and musculoskeletal disease researchers and physicians from around the world will meet today in London, UK for the opening of the largest scientific event in the field, the World Congress on Osteoporosis, Osteoarthritis and

Neuropsychiatric SLE - 2/3 Improved at 12 Months

Save

JAMA: SLE Review

Save

Drs. Caroline Siegel and Lisa Sammaritano (from HSS in NYC) have published an impressive overview of systemic lupus erythematosus (SLE) in JAMA. This timely, well-written review covers the many complexities of this multi-organ disorder that affects nearly 3.4 million people worldwide.

Seasonal Pathogens and Henoch-Schönlein Purpura

Save

Epidemiologic studies of Henoch-Schönlein purpura (HSP) have suggested seasonal variation in occurrence rates (higher from September-April, lower in June-August), suggesting a role for infectious triggers. The importance of infection was recently shown with nonpharmaceutical interventions (